Medicines Financial News

Biocon Biologics on Monday said it has inked a patent settlement agreement with Bayer Inc and Regeneron Pharmaceuticals Inc, paving the way for it to launch a biosimilar product in Canada. The settlement pact paves the way for the introduction of Yesafili, a proposed biosimilar to Eeylea (aflibercept) injection, in the Canadian market, Biocon Biologics said in a regulatory filing. Under the terms of the agreement, Biocon Biologics has secured a launch date for the product no later than July 1, 2025, it added.

SMS Pharma The European Directorate for the Quality of Medicines & HealthCare conducted a GMP inspection of the company’s API manufacturing facility in Andhra Pradesh from February 28 to March 1. A report on the same is awaited.

Central Council for Research in Ayurvedic Sciences (CCRAS) functioning under the ayush ministry, in collaboration with the Indian Council of Medical Research (ICMR), has initiated a clinical trial to study the efficacy and safety of Punarnavadi Mandura alone and in combination with Drakshavaleha, compared to iron folic acid, in the treatment of anaemia among non-pregnant women of the reproductive age group. The announcement on the multi-centre clinical trial on anaemia will be made by Union Minister of AYUSH Sarbananda Sonowal and Union Health Minister Mansukh Mandaviya on Monday, according to an official statement. The research study on anaemia has been titled «Efficacy and safety of Punarnavadi Mandura alone and in combination with Drakshavaleha compared to iron folic acid in the treatment of moderate iron deficiency anaemia among non-pregnant women of reproductive age group: a community-based three-arm multi-centre randomised controlled trial».

Mansukh Mandaviya on Saturday inaugurated 40 new facilities across the country to manufacture bulk drugs and medical devices to enhance self-reliance and reduce dependence on imports for such critical materials and equipment. Speaking at the inauguration ceremony here, Minister for Chemicals and Fertilisers Mansukh Mandaviya said the country has taken a big step towards self-reliance, with the commissioning of 27 new bulk drug facilities and 13 medical device manufacturing plants. The facilities, owned by various companies, were commissioned under the PLI Scheme for bulk drugs and medical devices, respectively.

Covid vaccine is not responsible for heart attacks, Union Health Minister Mansukh Mandaviya said today citing a study done by the Indian Council of Medical Research (ICMR). While speaking at ANI Dialogues 2024-Navigating India's Health Sector, Mandaviya said, «If someone has a stroke today, they think it is because of the Covid vaccine. ICMR has done a detailed study that the (Covid) vaccine is not responsible for heart attacks.» He added, «There are multiple reasons for heart attacks, like our lifestyle, tobacco and liquor consumption… Sometimes, misinformation goes among the people and a perception is formed for some time… But whatever decision we make, it should be data-based and scientific research-based.»

By Svea Herbst-Bayliss

BANGKOK (Reuters) — Thailand will ban the recreational use of marijuana by the end of this year, but continue allowing its use for medical purposes, the health minister told Reuters in an interview.

ALSO READ: BCCI terminates central contracts of Ishan Kishan and Shreyas Iyer. Check full contract list here Looking at Ishan Kishan's exclusion from BCCI's list, it appears the board was unhappy with him not participating in domestic cricket during periods when he was not representing the national team. Earlier on 17 December, when Ishan Kishan had left India's Tour of South Africa, the BCCI had said, "Mr Ishan Kishan has requested the BCCI to be released from the upcoming Test series against South Africa citing personal reasons.

Hindustan Times. The researchers and doctors at the institute have reportedly worked for 10 years and have now come up with a tablet which they claimed would stop the occurrence of cancer for the second time in patients.

Patanjali Foods fell by 4.13% to ₹1,555 apiece in today's early morning trade after the Supreme Court on Tuesday served a contempt notice to Ramdev-owned Patanjali Ayurved and its managing director Acharya Balakrishna for going back on their promise to not make "misleading claims" in advertisements for its medicines. Also Read: SC slaps contempt notice on Patanjali Ayurved for misleading ads The apex court also barred Patanjali from promoting products claimed to cure diseases such as heart ailments and asthma.

Zeno Health, which runs a chain of generic medicine-focussed pharmacies, has raised $25 million from investors led by Korean private equity firm STIC Investments. Existing investor Lightbox Ventures was a significant participant in the Series C funding round.

Patanjali Ayurved's Baba Ramdev and Acharya Balakrishnan and asked why contempt proceedings should not be initiated against them for violating its orders. The top court was hearing Indian Medical Association's plea seeking action against Baba Ramdev and Patanjali Ayurved for defaming evidence-based medicine The SC said that the government was sitting with its eyes closed and asked it to take action against Patanjali.

SIDBI ET MSME Conclave held in Rajkot saw a stellar turnout. From conversations around building financially resilient and competitive MSMEs to the challenges that need immediate solutions, the Rajkot edition aimed to understand the role of Gujarat in shaping a viable ecosystem for the MSME sector. Small and medium industries in the city are dominated by foundries, engineering & automobile works, and units that manufacture textiles, gold & silver jewellery, handicrafts, spices, medicines and wall clocks. Gujarat has the fourth-highest number of micro, small and medium enterprises in the country, after Maharashtra, Tamil Nadu and Uttar Pradesh, according to data provided by the Union government in Parliament last year.

Russia is close to creating cancer vaccines, says President Putin Animal studies are completed successfully, with clinical trials planned. The IIT-Madras researchers are currently working on addressing the safety and cost issues which are major challenges in the existing cancer medicines.

out-of-pocket expenditure (OOPE) on healthcare has been a significant worry for Indians. According to a 2022 WHO report, high OOPE on health impoverishes some 55 million Indians annually, with over 17% households incurring catastrophic levels of health expenditures every year. This high cost has serious cascading impacts, reveals a new Aiims report.

Uzbekistan sentenced 23 people to prison terms on Monday over the deaths of 68 children linked to contaminated cough syrups produced by India's Marion Biotech, following a six-month-long trial. The Central Asian nation had previously reported 65 deaths linked to the medicines, but last month the prosecutors at the Tashkent city court updated the death toll and said two more people had been charged during the hearings.

Individual pension plans stand out as a sterling retirement savings option for some demographics of entrepreneurs and incorporated business owners, particularly those with T4 income of more than $100,000 and over the age of 40.

PTI, the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST), which bestows this award to promising researchers in the state, recognized Veeraraghavan, who serves as a professor of electrical and computer engineering at Rice University's George R. Brown School of Engineering.

Seeking prompt diagnosis at a walk-in clinic can be a benefit for patients, sparing them potential wait for a family doctor appointment, especially as many provinces grapple with physician shortages.

₹20,824 per month on their needs, nearly 10 times of what the persons in the bottom 5% spend ( ₹2,001), the new Household Consumption Expenditure Survey (HCES) released by the statistics ministry showed. In rural areas, the ratio is slightly narrower, at seven times ( ₹1,373 vs ₹10,501). On average, a rural person spent ₹3,773 per month in 2022-23, compared to ₹1,430 recorded in the 2011-12 survey.

Cannabis stocks have been on a rollercoaster ride, going from a big boom in late 2019 to a crash in the following years.